(Q28343080)

https://api.crossref.org/works/10.1177/106002809202600210

2 December 2023

author name string

J. L. Chen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1313319

12 September 2022

J. M. Brocavich

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1313319

12 September 2022

A. Y. Lin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1313319

full work available at URL

12 September 2022

language of work or name

English

0 references

publication date

February 1992

0 references

http://www.theannals.com/cgi/content/abstract/26/2/193

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1313319

http://journals.sagepub.com/doi/pdf/10.1177/106002809202600210

12 September 2022

1 reference

https://api.crossref.org/works/10.1177/106002809202600210

Annals of Pharmacotherapy

2 December 2023

published in

0 references

volume

26

0 references

issue

2

0 references

page(s)

193-5

0 references

cites work

Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Cytomegalovirus retinitis and acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Severe but reversible neurotoxicity from acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Acyclovir: neurologic and renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Excessive serum concentrations of acyclovir and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Neurologic Symptoms Associated with Parenteral Acyclovir Treatment After Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Central nervous system side effects of ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Ranitidine-associated hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809202600210

Susceptibility of human herpesvirus 6 to acyclovir and ganciclovir

21 January 2018

3

1 reference

https://api.crossref.org/works/10.1177/106002809202600210

Antiviral activity and mechanism of action of ganciclovir

2 December 2023

4

1 reference

https://api.crossref.org/works/10.1177/106002809202600210

Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients

2 December 2023

5

1 reference

https://api.crossref.org/works/10.1177/106002809202600210

Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus

2 December 2023

9

1 reference

https://api.crossref.org/works/10.1177/106002809202600210

9-(1,3-Dihydroxy-2-propoxymethyl)guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome

2 December 2023

11

1 reference

https://api.crossref.org/works/10.1177/106002809202600210

Psychiatric side-effects of acyclovir in patients with chronic renal failure

2 December 2023

13

1 reference

https://api.crossref.org/works/10.1177/106002809202600210

Psychiatric side-effects with acyclovir

2 December 2023

14

1 reference

https://api.crossref.org/works/10.1177/106002809202600210

Major Depression with Psychotic Features Associated with Acyclovir Therapy

2 December 2023

17

1 reference

https://api.crossref.org/works/10.1177/106002809202600210

2 December 2023

Identifiers

release_mxyi6344sfbwtpvfjyzkhmpz7e

0 references

Fatcat ID

0 references